Patents by Inventor Yongxue HUANG

Yongxue HUANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12054502
    Abstract: A multifunctional immunity-targeted micromolecule anti-cancer medicine Citrate Bestazomib and preparation method and application thereof. The structure of the multifunctional immunity-targeted micromolecule anti-cancer medicine Bestazomib Citrate is shown as follows: The multifunctional immunity-targeted micromolecule anti-cancer medicine Citrate Bestazomib has an activity-inhibiting effect on APN/CD13, also has an activity-inhibiting effect on tumor proteasome, and can be applied to the development of medicines for treating malignant tumors.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: August 6, 2024
    Assignee: SHANDONG HUBBLE KISEN BIOLOGICAL TECHNONLOGY CO., LTD.
    Inventors: Wenfang Xu, Jian Zhang, Yuqi Jiang, Xiaobo Xu, Xiaoyang Li, Leqiao Tan, Yongxue Huang, Xuejian Wang, Zhen Zhang
  • Publication number: 20210300949
    Abstract: A multifunctional immunity-targeted micromolecule anti-cancer medicine Citrate Bestazomib and preparation method and application thereof. The structure of the multifunctional immunity-targeted micromolecule anti-cancer medicine Bestazomib Citrate is shown as follows: The multifunctional immunity-targeted micromolecule anti-cancer medicine Citrate Bestazomib has an activity-inhibiting effect on APN/CD13, also has an activity-inhibiting effect on tumor proteasome, and can be applied to the development of medicines for treating malignant tumors.
    Type: Application
    Filed: August 5, 2019
    Publication date: September 30, 2021
    Inventors: Wenfang XU, Jian ZHANG, Yuqi JIANG, Xiaobo XU, Xiaoyang LI, Leqiao TAN, Yongxue HUANG, Xuejian WANG, Zhen ZHANG